Want to see IN:AKUMS full AI Analyst Report?
AKUMS Stock Chart & Stats
₹684.40
-₹11.70(-1.70%)
At close: 4:00 PM EDT
₹684.40
-₹11.70(-1.70%)
Day’s Range― - ―
52-Week Range₹410.10 - ₹839.25
Previous CloseN/A
Volume178.53K
Average Volume (3M)11.86K
Market Cap
₹120.91B
Enterprise Value₹56.30B
Total Cash (Recent Filing)₹16.78B
Total Debt (Recent Filing)₹902.87M
Price to Earnings (P/E)40.4
Beta1.24
Next Earnings
Nov 09, 2026EPS Estimate
6.35Next Dividend Ex-DateN/A
Dividend Yield0.39%
Share Statistics
EPS (TTM)12.42
Shares Outstanding157,393,980
10 Day Avg. Volume6,441
30 Day Avg. Volume11,862
Financial Highlights & Ratios
PEG Ratio-1.07
Price to Book (P/B)2.15
Price to Sales (P/S)1.64
P/FCF Ratio7.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)27.16
Revenue Forecast (FY)₹49.50B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRevenue expansion across the period indicates increasing business scale and continued demand for Akums’ contract development and manufacturing services. A larger revenue base can support operating leverage, broaden customer relationships, and strengthen the company’s ability to reinvest in compliant manufacturing capacity.
Conservative LeverageThe sharp reduction in leverage materially strengthens financial resilience and reduces the burden of debt service. A stronger capital base gives Akums greater flexibility to fund capacity, absorb business volatility, and pursue growth without relying as heavily on external borrowing.
Improved Cash GenerationStrong recent operating and free cash flow demonstrates that the return to profitability is translating into substantial internal funding. This supports investment, debt reduction, and shareholder-oriented capital allocation while reducing dependence on incremental financing for ongoing business needs.
Bears Say
Margin CompressionThe sharp FY26 decline in gross and net margins shows that revenue growth has not translated consistently into profitability. If cost pressure, product mix changes, or other reported influences persist, earnings quality and the durability of returns could remain under pressure.
Cash Flow VolatilityAlthough recent cash generation is strong, the multi-year record remains uneven and FY26 free cash flow declined from the prior year. Such volatility can complicate investment planning, reduce confidence in recurring cash earnings, and constrain the consistency of internally funded growth.
Declining EPS GrowthNegative reported EPS growth indicates that per-share earnings momentum is currently weaker than the company’s revenue trend. Unless profitability stabilizes, this can limit the benefits of scale for shareholders and signal that cost, mix, or other earnings pressures are offsetting top-line progress.
Akums Drugs and Pharmaceuticals Limited News
AKUMS FAQ
What was Akums Drugs and Pharmaceuticals Limited’s price range in the past 12 months?
Akums Drugs and Pharmaceuticals Limited lowest stock price was ₹410.10 and its highest was ₹839.25 in the past 12 months.
What is Akums Drugs and Pharmaceuticals Limited’s market cap?
Akums Drugs and Pharmaceuticals Limited’s market cap is ₹120.91B.
When is Akums Drugs and Pharmaceuticals Limited’s upcoming earnings report date?
Akums Drugs and Pharmaceuticals Limited’s upcoming earnings report date is Nov 09, 2026 which is in 25 days.
How were Akums Drugs and Pharmaceuticals Limited’s earnings last quarter?
Akums Drugs and Pharmaceuticals Limited released its earnings results on Aug 08, 2026. The company reported ₹6.45 earnings per share for the quarter, beating the consensus estimate of ₹6.1 by ₹0.35.
Is Akums Drugs and Pharmaceuticals Limited overvalued?
According to Wall Street analysts Akums Drugs and Pharmaceuticals Limited’s price is currently Overvalued.
Does Akums Drugs and Pharmaceuticals Limited pay dividends?
Akums Drugs and Pharmaceuticals Limited pays a Notavailable dividend of ₹3 which represents an annual dividend yield of 0.39%. See more information on Akums Drugs and Pharmaceuticals Limited dividends here
What is Akums Drugs and Pharmaceuticals Limited’s EPS estimate?
Akums Drugs and Pharmaceuticals Limited’s EPS estimate is 6.35.
How many shares outstanding does Akums Drugs and Pharmaceuticals Limited have?
Akums Drugs and Pharmaceuticals Limited has 157,393,980 shares outstanding.
What happened to Akums Drugs and Pharmaceuticals Limited’s price movement after its last earnings report?
Akums Drugs and Pharmaceuticals Limited reported an EPS of ₹6.45 in its last earnings report, beating expectations of ₹6.1. Following the earnings report the stock price went down -2.69%.
Which hedge fund is a major shareholder of Akums Drugs and Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:AKUMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Akums Drugs and Pharmaceuticals Limited
Akums Drugs & Pharmaceuticals Ltd. is an Indian-based company, established in 2004 and headquartered in Delhi, that operates globally as a manufacturer and supplier of both finished pharmaceutical products and active pharmaceutical ingredients (APIs). Its diverse product range encompasses conventional drugs, traditional Ayurvedic and herbal remedies, personal care items including toiletries, nutraceuticals, food and dietary supplements, dermatological and cosmetic products, and healthcare and hospital supplies, along with over-the-counter (OTC) solutions. The company also deals in excipients and various chemical compounds. Akums develops and markets its own branded formulations across a variety of dosage forms, such as tablets, capsules, injectables, ophthalmic preparations, and soft gelatin capsules. These products address a broad spectrum of therapeutic areas, including gynaecology, cardiology, orthopaedics, pediatrics, dermatology, anti-infectives, pain management, and gastroenterology. Furthermore, Akums Drugs & Pharmaceuticals provides services as a pharmaceutical contract development and manufacturing organization (CDMO).
Technical Analysis
Glenmark Life Sciences Limited
―
Jubilant Pharmova Limited
―
Shilpa Medicare Limited
―
Strides Pharma Science Ltd
―
Sudeep Pharma Limited
―